| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7144861 | LILLY | Stabilized teriparatide solutions |
Dec, 2018
(5 years ago) | |
| US7550434 | LILLY | Stabilized teriparatide solutions |
Dec, 2018
(5 years ago) | |
| US6770623 | LILLY | Stabilized teriparatide solutions |
Dec, 2018
(5 years ago) | |
| US6977077 | LILLY | Method of increasing bone toughness and stiffness and reducing fractures |
Aug, 2019
(4 years ago) | |
| US7163684 | LILLY | Method of increasing bone toughness and stiffness and reducing fractures |
Aug, 2019
(4 years ago) | |
| US7351414 | LILLY | Method of reducing the risk of bone fracture |
Aug, 2019
(4 years ago) | |
| US7517334 | LILLY | Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose |
Mar, 2025
(10 months from now) | |
Forteo is owned by Lilly.
Forteo contains Teriparatide.
Forteo has a total of 7 drug patents out of which 6 drug patents have expired.
Expired drug patents of Forteo are:
- US7144861
- US7550434
- US6770623
- US6977077
- US7163684
- US7351414
Forteo was authorised for market use on 25 June, 2008.
Forteo is available in solution;subcutaneous dosage forms.
Forteo can be used as forteo is indicated for the treatment of post menopausal women with osteoporosis who are at high risk for fracture, method of treating osteoporosis in a post-menopausal woman at risk for fracture, method for the treatment of a woman with osteoporosis and at risk for bone fracture, a method of treating osteoporosis.
The generics of Forteo are possible to be released after 25 March, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-302) | Nov 16, 2023 |
| New Indication(I-602) | Jul 22, 2012 |
Drugs and Companies using TERIPARATIDE ingredient
Market Authorisation Date: 25 June, 2008
Treatment: A method of treating osteoporosis; Forteo is indicated for the treatment of post menopausal women with osteoporosis who are at high risk for fracture; Method of treating osteoporosis in a post-menopau...
Dosage: SOLUTION;SUBCUTANEOUS
FORTEO family patents
